218 related articles for article (PubMed ID: 23217210)
1. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Johnson BC; Pauly GT; Rai G; Patel D; Bauman JD; Baker HL; Das K; Schneider JP; Maloney DJ; Arnold E; Thomas CJ; Hughes SH
Retrovirology; 2012 Dec; 9():99. PubMed ID: 23217210
[TBL] [Abstract][Full Text] [Related]
2. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
4. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
[TBL] [Abstract][Full Text] [Related]
5. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
6. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
[TBL] [Abstract][Full Text] [Related]
7. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
[TBL] [Abstract][Full Text] [Related]
8. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
Das K; Bauman JD; Clark AD; Frenkel YV; Lewi PJ; Shatkin AJ; Hughes SH; Arnold E
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1466-71. PubMed ID: 18230722
[TBL] [Abstract][Full Text] [Related]
9. Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase.
Kuroda DG; Bauman JD; Challa JR; Patel D; Troxler T; Das K; Arnold E; Hochstrasser RM
Nat Chem; 2013 Mar; 5(3):174-81. PubMed ID: 23422558
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-
Yang Y; Kang D; Nguyen LA; Smithline ZB; Pannecouque C; Zhan P; Liu X; Steitz TA
Elife; 2018 Jul; 7():. PubMed ID: 30044217
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.
Reinheimer C; Doerr HW; Stürmer M
J Clin Virol; 2012 Mar; 53(3):248-50. PubMed ID: 22209291
[TBL] [Abstract][Full Text] [Related]
13. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
14. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Tian XT; Xie L
Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.
Chen X; Zhan P; Li D; De Clercq E; Liu X
Curr Med Chem; 2011; 18(3):359-76. PubMed ID: 21143120
[TBL] [Abstract][Full Text] [Related]
16. Biochemical mechanism of HIV-1 resistance to rilpivirine.
Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z; Norden PR; Hachiya A; Parniak MA; Xu HT; Wainberg MA; Sarafianos SG
J Biol Chem; 2012 Nov; 287(45):38110-23. PubMed ID: 22955279
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.
Lansdon EB; Brendza KM; Hung M; Wang R; Mukund S; Jin D; Birkus G; Kutty N; Liu X
J Med Chem; 2010 May; 53(10):4295-9. PubMed ID: 20438081
[TBL] [Abstract][Full Text] [Related]
18. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW
Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973
[TBL] [Abstract][Full Text] [Related]
19. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
20. Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase.
Kar P; Knecht V
J Phys Chem B; 2012 Jun; 116(22):6269-78. PubMed ID: 22574920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
